
Arthrosamid and the Medial Knee: Exploring Targeted Relief for Inner-Compartment Osteoarthritis
Medial-compartment knee osteoarthritis, often worsened by varus alignment, causes significant inner-knee pain due to cartilage wear. Arthrosamid, a polyacrylamide hydrogel injection, provides targeted cushioning to reduce bone-on-bone contact, offering effective symptom relief and improved function. Administered by experts like Professor Paul Lee at the London Cartilage Clinic, this minimally invasive treatment is tailored for patients with confirmed medial damage who have not yet needed surgery. Research indicates Arthrosamid benefits older patients with less severe disease, delivering pain relief lasting up to 24 months. Comprehensive patient evaluation and follow-up care ensure optimal outcomes. While not restoring cartilage, Arthrosamid represents a promising non-surgical option to slow progression and enhance mobility in medial-compartment knee osteoarthritis.




